Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Braze Inc (BRZE) vs Novo Nordisk A/S (NVO) Price & Performance

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Braze Inc vs Novo Nordisk A/S — how do they compare? Braze Inc trades at $28.27 (market cap $3.18B), while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 65.4× Braze Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Braze Inc pays none. Which is the better fit depends on your goals.

BRZENVO
Market Cap
$3.18B$207.85B
Sector
TechnologyHealth
52-Week High
$36.19$63.98
52-Week Low
$15.79$35.29
Enterprise Value
$2.87B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Braze Inc

BRZE trades at $27.68, down 3.72% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is strong at 30% year-over-year, though the company remains unprofitable with a net margin of -15.51%. Recent news highlights insider selling and a 15% weekly rebound amid AI sector momentum.

The stock offers growth exposure with a consensus price target of $34.78, but risks include persistent losses, competitive pressures, and high valuation multiples. Analyst sentiment is overwhelmingly bullish, yet profitability challenges and insider sales warrant caution for investors seeking near-term returns.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Braze Inc

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.

Read more on BRZE

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO